Flutialfa Trio 100 Rota Capsule contains Vilanterol 25 mcg, Fluticasone 100 mcg, and Umeclidinium 62.5 mcg, a triple combination therapy designed for the long-term management of COPD and asthma.
Vilanterol is a long-acting beta-2 agonist (LABA) that relaxes airway smooth muscles for bronchodilation, Umeclidinium is a long-acting muscarinic antagonist (LAMA) providing additional airway relaxation, and Fluticasone is an inhaled corticosteroid that reduces airway inflammation. Together, they help improve lung function, reduce exacerbations, and enhance symptom control.
Clinically, Flutialfa Trio 100 Rota Capsule is suitable for patients with moderate to severe COPD or asthma who require triple inhaled therapy for optimal disease control. The capsule formulation ensures consistent dosing and patient compliance.
From a business perspective, Flutialfa Trio 100 Rota Capsule strengthens the respiratory therapy segment, widely prescribed in pulmonology and respiratory clinics, offering steady demand, repeat prescriptions, and trusted clinical efficacy, making it a high-value addition for pharma partners.